CTOs on the Move

Hawaii Behavioral Health

www.hibh.org

 
Hawaii Behavioral Health is the leading resource for community-based educational, social, and behavioral health services in Hawaii.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.hibh.org
  • 1330, Ala Moana Boulevard
    Honolulu, HI USA 96814
  • Phone: 808.585.1424

Executives

Name Title Contact Details

Similar Companies

VersaPharm Incorporated

VersaPharm Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

MOVA Pharmaceuticals

MOVA Pharmaceuticals is a Caguas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.

Xpress Wellness Urgent Care

Xpress Wellness provides urgent care, primary care, and occupational medicine. Walk in, check in online, or schedule a virtual visit today.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.